Primary Job Title CEO & President Primary Organization 
Cidara Therapeutics
Location San Diego, California, United States Regions Greater San Diego Area, West Coast, Western US Gender Male
LinkedIn View on LinkedIn
Jeff Stein, Ph.D., their President and Chief Executive Officer, was CEO of Trius Therapeutics, Inc., a publicly-traded pharmaceutical company, from its founding in 2007 until its acquisition by Cubist Pharmaceuticals, Inc. in September 2013. During his tenure, Trius developed the antibacterial drug tedizolid, which received marketing approval from
the U.S. Food and Drug Administration in June 2014; tedizolid is now marketed under the name Sivextro. From 2005 to 2010, Dr. Stein was a venture partner at Sofinnova Ventures, a biotech venture capital fund. Prior to joining Sofinnova, Dr. Stein was co-founder and Chief Scientific Officer at Quorex Pharmaceuticals, Inc. from 1999 until its acquisition by Pfizer Pharmaceuticals, Inc. in 2005. He has also served as a Principal Scientist with Diversa Corporation and the Agouron Institute. Dr. Stein currently serves on the Board of Directors of Great Lakes Pharmaceuticals, Inc., a private biopharmaceutical company, and Paratek Pharmaceuticals, a publicly-traded biopharmaceutical company. He was also founding Chairman and President of the Antibiotics Working Group, an industry led non-profit organization. Dr. Stein holds a B.S. in marine biology and an M.S. in biology from California State University—Long Beach and a Ph.D. in marine biology from the University of California, San Diego. Dr. Stein conducted his postdoctoral research in bacterial genetics as an Alexander Hollaender Distinguished Postdoctoral Fellow at the California Institute of Technology.
